anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Genomic technologies have transformed clinical genetic testing, underlining the importance of accurate molecular genetic diagnoses. Variant classification, ranging from benign to pathogenic, is fundamental to these tests. However, variant reclassification, the process of reassigning the pathogenicity of variants over time, poses challenges to diagnostic legitimacy. This review explores the medical and scientific literature available on variant reclassification, focusing on its clinical implications.Variant reclassification is driven by accruing evidence from diverse sources, leading to variant reclassification frequency ranging from 3.6% to 58.8%. Recent studies have shown that significant changes can occur when reviewing variant classifications within 1 year after initial classification, illustrating the importance of early, accurate variant assignation for clinical care.Variants of uncertain significance (VUS) are particularly problematic. They lack clear categorisation but have influenced patient treatment despite recommendations against it. Addressing VUS reclassification is essential to enhance the credibility of genetic testing and the clinical impact. Factors affecting reclassification include standardised guidelines, clinical phenotype-genotype correlations through deep phenotyping and ancestry studies, large-scale databases and bioinformatics tools. As genomic databases grow and knowledge advances, reclassification rates are expected to change, reducing discordance in future classifications.Variant reclassification affects patient diagnosis, precision therapy and family screening. The exact patient impact is yet unknown. Understanding influencing factors and adopting standardised guidelines are vital for precise molecular genetic diagnoses, ensuring optimal patient care and minimising clinical risk.
PROBLEM TO BE SOLVED: To obtain the subject composition having excellent stability at a high temperature near a specific temperature such as bodily temperature and useful for pharmaceuticals, cosmetics, foods, etc., by including a benzyloxycarbonylamino acid derivative. SOLUTION: A compound expressed by the formula (R1 is benzyl; R2 is a 6-22C alkylamino, a 6-22C alkenylcarbonylphenoxy, etc.; R3 is a 1-4C alkyl; (n) is 1-4) is produced by benzyloxycarbonylating the amino group of an amino acid, etc., with benzyl chloroformate, etc., and condensing the product to a corresponding alkylcarbonylphenol, etc., using an esterifying agent as a catalyst. The objective composition can be produced by using the compound as a component in an amount of 0.1-100 pts.wt., preferably 0.5-90 pts.wt. based on 1 pt.wt. of an oily component.
A mobile healthcare hub includes a processor, memory coupled to the processor and a display coupled to the processor. A communications module includes a mobile communication device configured to communicate with one or more monitoring devices. The one or more monitoring devices are configured to store measurement data and/or historic data for a particular patient. The mobile communications device is connected to the one or more monitoring devices upon entering a communication envelope. An information monitoring module is configured to receive, consolidate and process the measurement data and/or historic data for the particular patient from the one or more monitoring devices based upon relevance and context. A display formatting module is configured to receive the measurement data and/or historic data for the particular patient and format the measurement data and/or historic data for display on the display.
Prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) methods will be employed to collect saliva and evaluate transcriptome markers for early pre-diabetes and type II diabetes identification. At risk patients will have fasting blood glucose and insulin levels measured along with hemoglobin A1c and 2 hour post-prandial glucose levels. Saliva samples will be stored and will be analyzed after pre-specifying a panel of mRNAs and a multi marker model for validation. The pre-specified mRNAs and multi-marker model will be determined after analysis of data from a currently ongoing case-control study. After analyzing the data from this prior trial a validation plan will be locked before analysis of the prospectively collected specimens. Pre-diabetes will be defined based on abnormal glucose tolerance tests. Insulin resistance will be calculated as HOMA IR. The diagnostic value of the salivary transcriptome for will be compared with that of hemoglobin A1c and fasting blood glucose for the detection of pre-diabetes, insulin resistance and type II diabetes.
PURPOSE:To obtain a medicine for entoptic perfusion-washing and for preservation of an eyeball, containing a phosphoric acid diester compound of ascorbic acid and tocopherol or its pharmaceutically permissible salt as the active component and having an excellent entoptic tissue-protecting effect. CONSTITUTION:This medicine for entoptic perfusion-washing and for preservation of an eyeball contains a phosphoric acid diester compound of the formula (R1 and R2 are each H or methyl) or its pharmaceutically permissible salt. The compound of the formula is synthesized by reacting ascorbic acid with tocopherol. In addition, the compound of the formula is remarkably low in toxicity, excellent in safety and, therefore, advantageously used in various kinds of ophthalmic operations or in preservation of an eyeball. In the case a preparation containing this compound is used as an entoptic perfusion-washing agent, the concentration of the compound of the formula is about 0.5 to 10mug/ml. In the case this preparation is used as a medicine for preservation of an eyeball, the concentration of the compound of the formula is preferably 5X10<-8> to 5X10<-5>g/ml. The compound of the formula is especially excellent in protection of corneal (endothelial) cells which are extremely apt to receive a biological damage in an ophthalmic operation.
Fecal microbiota transplantation (FMT) is performed by experienced endoscopists through flexible endoscopy into the afferent limb. The second FMT is installed via transanal catheter into the pouch 4 weeks after the first FMT.
The prehabilitation (PREHAB) program focuses on total-body physical exercises and pelvic floor muscle exercises (PFMX). The total-body exercise prescription will consist of 60 minutes of home-based, unsupervised exercise on 3-4 days per week, alternating between aerobic and resistance training. Each session will include: a 5-minute warm-up, 25 minutes of aerobic exercise, 25 minutes of resistance training (5 exercises targeting major muscle groups), and a 5-minute cool-down. Training intensity progression will occur throughout the intervention. Participants will be provided with resistance bands, a stability ball, and an exercise mat. The PFMX prescription will include a gradual increase in PFMX exercises from 60 per day during weeks 1-2, 120 per day during weeks 3-4, and 180 per day during weeks 5-6 until the surgery date. The total number of repetitions of the PFMXs will be divided equally between the rhythmic and sustained contractions.
BACKGROUND: Chronic kidney disease (CKD) is highly connected to inflammation and oxidative stress. Both favour the development of cancer in CKD patients. Serum apolipoprotein A-IV (apoA-IV) concentrations are influenced by kidney function and are an early marker of kidney impairment. Besides others, it has antioxidant and anti-inflammatory properties. Proteomic studies and small case-control studies identified low apoA-IV as a biomarker for various forms of cancer; however, prospective studies are lacking. We therefore investigated whether serum apoA-IV is associated with cancer in the German Chronic Kidney Disease (GCKD) study.
METHODS: These analyses include 5039 Caucasian patients from the prospective GCKD cohort study followed for 6.5 years. Main inclusion criteria were an eGFR of 30-60 mL/min/1.73m2 or an eGFR > 60 mL/min/1.73m2 in the presence of overt proteinuria.
RESULTS: Mean apoA-IV concentrations of the entire cohort were 28.9 ± 9.8 mg/dL (median 27.6 mg/dL). 615 patients had a history of cancer before the enrolment into the study. ApoA-IV concentrations above the median were associated with a lower odds for a history of cancer (OR = 0.79, p = 0.02 when adjusted age, sex, smoking, diabetes, BMI, albuminuria, statin intake, and eGFRcreatinine). During follow-up 368 patients developed an incident cancer event and those with apoA-IV above the median had a lower risk (HR = 0.72, 95%CI 0.57-0.90, P = 0.004). Finally, 62 patients died from such an incident cancer event and each 10 mg/dL higher apoA-IV concentrations were associated with a lower risk for fatal cancer (HR = 0.62, 95%CI 0.44-0.88, P = 0.007).
CONCLUSIONS: Our data indicate an association of high apoA-IV concentrations with reduced frequencies of a history of cancer as well as incident fatal and non-fatal cancer events in a large cohort of patients with CKD.
The goal of the study is to obtain preliminary data and initial estimates of the FLT ability-PET to identify pathCR patients who have esophageal carinoma or non-small cell lung cancer and undergo Neoadjuvant Therapy (Chemoradiotherapy, Chemotherapy or Radiation Therapy) prior to surgery. Achievement in pathCR after pre-operative Neoadjuvant Therapy is associated with improved patient outcomes; however, there is no effective method to predict pathological response before surgery. Thus, a patient with pathCR , for whom esophagectomy or thoracoscopy may be unnecessary, still undergoes surgery and faces the prohibitive side effects of this surgical procedure. Additionally, Neoadjuvant Therapy is associated with considerable morbidities and tool to predict and avoid ineffective therapy are lacking. Because deregulated proliferation is one of the hallmarks of cancer and its proliferation rate is associated with aggressive biologic behavior and response to therapy, imaging the proliferative state of cancer cells by non-invasive functional imaging is of great interest. Recently 18F-FLT (3'deoxy33'-18F- ﬂuorothymidine) has been reported as a promising PET radiopharmaceutical for imaging cancer proliferation and has been validated in several in vitro \& in vivo models. However, only a few studies addressed its role in depicting changes in cancer proliferation and assessing response to Neoadjuvant Therapy, and none of these studies have focused on esophageal cancer and lung cancer. We propose to conduct a pilot study to learn the optimal FLT PET imaging timepoint during the early course of Neoadjuvant Therapy that has the highest predictive value for pathCR in patients with esophageal cancer or lung cancer.
The invention relates to a preparation method of violet gold black ginseng. The preparation method comprises carrying out wall breaking treatment on cleaned ginseng, carrying out drying, and carrying out fermentation treatment under the conditions of control of a temperature and humidity. Through the preparation method, in violet gold black ginseng preparation, high-content secondary ginsenoside components Rg3 and Rh2 are formed. A detection result shows that compared with black ginseng obtained by the traditional method, the violet gold black ginseng has ginsenoside Rg3 content improved by 25-26% and ginsenoside Rh2 content improved by 3 times, and obviously improves health care effects and medicinal value. The preparation method is not influenced by natural conditions, has large scale batch production feasibility, realizes violet gold black ginseng product quality data control and prevents difference of each batch of products. The violet gold black ginseng has a sweet-waxy taste.
The KTP:YAG laser is based on the principle of passing Nd:YAG laser light through a KTP crystal. This halves the wavelength of the emitted laser to 532 nm and doubles its frequency. The emitted light is a visible green light, which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. Prostate tissue is vaporized leaving an appropriate cavity for voiding.
An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from Rubus spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.
PCT No. PCT/JP95/00848 Sec. 371 Date Dec. 23, 1996 Sec. 102(e) Date Dec. 23, 1996 PCT Filed Apr. 27, 1995 PCT Pub. No. WO95/28925 PCT Pub. Date Nov. 2, 1995A pharmaceutical agent comprising an ascorbic acid, a derivative thereof or a salt thereof (ascorbic acids) as an active ingredient, for selectively inducing apoptosis of unnecessary or pathogenic cells to thereby prevent and/or treat diseases caused by said cells; a method for the prophylaxis and/or treatment of diseases caused by unnecessary or pathogenic cells, comprising selectively inducing apoptosis of said cells by the use of ascorbic acids; and use of ascorbic acids for the production of a pharmaceutical agent for selectively inducing apoptosis of unnecessary or pathogenic cells to thereby prevent and/or treat diseases caused by said cells. The ascorbic acids are low toxic and selectively induce apoptosis of unnecessary or pathogenic cells. Therefore, they are useful for the prophylaxis and/or treatment of the diseases caused by said cells. For example, they serve for use as anticancer agents and carcinostatic agents, as well as for the prophylaxis and/or treatment of many diseases caused by various viral infections. In particular, since they selectively induce apoptosis of unnecessary or pathogenic cells, they are useful for the prophylaxis and/or treatment of HIV viral infections and the prophylaxis and/or treatment of acquired immune deficiency syndrome (AIDS).
Placebo tablets, 2 tablets t.i.d. for 84 days.
PURPOSE:To prevent discoloration and the generation of an irritating odor and produce a branched polysaccharide having a high content of 1, 6 linkages by the moist heat treatment of a polysaccharide containing an equilibrium amount of an adsorbed organic or inorganic acid. CONSTITUTION:A polysaccharide (e.g. starch or glucan) containing an equilibrium amount of an adsorbed organic acid (e.g. acetic or citric acid) or inorganic acid (e.g. hydrochloric or sulfuric acid) is peferably mixed with a monosaccharide and/or oligosaccharide and then subjected to moist heat treatment to produce a high content of 1, 6 linkages in the polysaccharide molecule. It is more desirable to increase the content of 1, 6 linkages in the polysaccharide molecule by at least 5% through the treatment. The equilibrium amounts of adsorbed organic and inorganic acids respectively are preferably 1-10wt.% and 0.03-0.1wt.% based on the polysaccharide used.
The present invention relates to methods of treating eustachian tube dysfunction using surfactants. In particular, it relates to the delivery of surfactants by inhalation to the eustachian tube to reduce its opening pressure. The surfactant compositions suitable for use in the invention are obtained from natural sources or produced synthetically. Bovine pulmonary surfactant is one example that is commercially available. The surfactant compositions are delivered by inhalation via the nasal and/or oral cavities as a liquid aerosol or in a dry powder formulation. A wide variety of uses is encompassed by the present invention including, but not limited to, the treatment of otologic disorders associated with eustachian tube dysfunction such as otitis media and dysfunction that results from acute changes in altitude.
The invention relates to an automatic method for selecting imaging parameters for an imaging method, a corresponding imaging method and a corresponding imaging device comprising a detection algorithm (Detection Algorithm) and a selection algorithm (Selection Algorithm). This enables the creation of at least one list of fitness values for possible clinical indications. The list is based on image data. The creation of the list is done by means of a detection algorithm. Furthermore, at least one imaging parameter is selected. At least one imaging parameter is adapted to generate image data enabling a maximum variation of the plausibility values in the list. The selection of the at least one imaging parameter is performed by means of a selection algorithm.
BACKGROUND: Pigmented villonodular synovitis is a rare yet locally invasive disorder impacting synovial tissues. This case report delineates the atypical manifestation of pigmented villonodular synovitis in the talonavicular joint, detailing its diagnostic complexity and successful management.
CASE PRESENTATION: A 56-year-old Iranian patient with a 4-year history of chronic ankle pain, initially diagnosed with degenerative joint disease post-trauma based on imaging, underwent talonavicular fusion surgery. An unexpected pigmented villonodular synovitis mass was encountered during the procedure. Subsequent interventions encompassed tumor resection, talonavicular joint fusion, and allograft bone grafting. Despite the initial intervention, persistent pain and nonunion necessitated a secondary procedure, involving joint surface curettage and autograft bone grafting. At the 12-month follow-up, the patient remained pain-free without tumor recurrence.
CONCLUSION: This case report highlights the significance of considering pigmented villonodular synovitis as a crucial differential diagnosis in chronic ankle pain, even when there is evidence of degenerative joint disease and a history of trauma. Magnetic resonance imaging serves a crucial role in accurate diagnosis. Treatment necessitates precise tumor removal, appropriate bone grafting techniques and secure fixation.
LEVEL OF EVIDENCE: IV.
Community-acquired MRSA infections are increasingly common in the community and in particular among certain groups of which soldiers are one. Many researchers and clinicians have postulated that one method to prevent infections is to selectively eradicate CA-MRSA in those who are colonized with the pathogen. The two main purposes of the study are: to determine if selective CA-MRSA eradication in subjects reduces infections in the CA-MRSA colonized individual; and to determine if selective CA-MRSA eradication in subjects reduces infections in the study cohort. Other information concerning CA-MRSA includes: prevalence, risk factors, and virulence data. The population will be soldiers enrolled in the combat medic training class at Ft. Sam Houston. We will enroll approximately 3000 soldiers over a two year period. After informed written consent, we will culture their anterior nares nares and administer questionnaires at the beginning and at the end of the study, following them prospectively for infections. The follow-up period will be 16 weeks. For those with CA-MRSA in their nares, they will be randomized (by cohort) to receive either 5 days of mupirocin or placebo.
PURPOSE: An antibody which specifically binds to interleukin-15 or TNF(tumor necrosis factor) or antigen-binding fragment thereof are provided to treat autoimmune diseases. CONSTITUTION: An antibody which specifically binds to interleukin-15 or antigen fragment thereof comprises heavy chain variable region and light chain variable region. The heavy chain variable region is a IL-15VH1(VH3) comprising heavy chain CDR(complementary determining regions ) of sequence numbers 1, 2, and 3. The light chain variable region is HuVLκ1-30(VLκ1) containing light chain CDR(complementary determining regions ) of sequence numbers 16, 17, and 18. A composition for treating inflammatory autoimmune disease contains the antibody and fragment thereof. The autoimmune disease is rheumatoid arthritis.
A double-stranded cDNA molecule which includes DNA encoding human manganese super oxide dismutase has been created. The sequence of one strand of a double- stranded DNA molecule which encodes human manganese superoxide dismutase has been discovered. Such mole- cules may be introduced in procaryotic, e.g., bacteri- al, or eukaryotic, e.g. , yeast or mammalian, cells and the resulting cells cultured or grown under suitable conditions sa as to produce human manganese superoxide dismutase or analogs thereof which may then be recov- ered. Human MnSOD or analogs thereof may be used to catalyze the reduction of superoxide radicals, reduce reperfusion injury, prolong the survival time of iso- lated organs, or treat inflammations. The invention also concerns a method of producing enzy- matically active human manganese superoxide dismutase or an analog thereof in a bacterial cell which contains and is capable of expressing a DNA sequence encoding the superoxide dismutase by maintaining the bacterial cell under suitable conditions and in a suitable pro- duction medium. The production medium is supplemented with an amount of Mn++ so that the concentration of Mn++ in the medium is greater than about 2 ppm. This invention also concerns a method of recovering purified enzymatically active manganese super oxide dismutase from bacterial cells.
Pediatric optic pathway/hypothalamic gliomas (OPHG) pose challenges in treatment due to their location and proximity to vital structures. Surgical resection plays a key role in the management of OPHG especially when the tumor exhibits mass effect and causes symptoms. However, data regarding outcomes and complications of surgical resection for OPHG remains heterogenous. The authors performed a systematic review on pediatric OPHG in four databases: PubMed, EMBASE, Cochrane Library, and Google Scholar. We included studies that reported on the visual outcomes and complications of OPHG resection. A meta-analysis was performed and reported per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. A total of 26 retrospective studies were included. Seven hundred ninety-seven pediatric patients with OPHG undergoing surgical resection were examined. A diagnosis of NF1 was confirmed in 9.7%. Gross total resection was achieved in 36.7%. Intraorbital optic pathway gliomas showed a significantly higher gross total resection rate compared to those located in the chiasmatic/hypothalamic region (75.8% vs. 9.6%). Postoperatively, visual acuity improved in 24.6%, remained unchanged in 68.2%, and worsened in 18.2%. Complications included hydrocephalus (35.4%), anterior pituitary dysfunction (19.6%), and transient diabetes insipidus (29%). Tumor progression post-resection occurred in 12.8%, through a mean follow-up of 53.5 months. Surgical resection remains an essential strategy for treating symptomatic and large pediatric OPHG and can result in favorable vision outcomes in most patients. Careful patient selection is critical. Patients should be monitored for hydrocephalus development postoperatively and followed up to assess for tumor progression and adjuvant treatment necessity.